Gilead’s HIV franchise generated $19.612B in 2024, but faces future funding challenges. Learn why GILD stock is a "Hold" amid ...

The Post caught up with several stars and crew members of “The Handmaid’s Tale” at the show’s sixth and final season premiere ...

In the latest market close, Gilead Sciences (GILD) reached $112.39, with a +0.45% movement compared to the previous day. The stock outperformed the S&P 500, which registered a daily loss of 4.84%. On ...

A lot has happened since we first met June Osborne (Elizabeth Moss) and other key figures in 'The Handmaid's Tale'. Here's a ...

PEPFAR had been set to lead the rollout of Gilead Science's lenacapavir, which has been hailed as a "miracle" of HIV ...

"We tried not to make the same show — it's got younger voices, it's got a completely different feel and a completely ...

Gilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some ...

With the FDA appearing to be undergoing major disruption under new leadership, BofA analyst Tim Anderson says one way to assess the risk from ...

Hulu's decision to pick up The Testaments signifies a strategic transition within the streaming service's narrative landscape. Set four years after the end of The Handmaid’s Tale, the sequel will ...

The final season of "The Handmaid's Tale," premiering April 8 on Hulu, expands the themes and story of Margaret Atwood's ...

Hulu announced that it is developing a series based on Margaret Atwood's 2019 novel "The Testaments," which is a follow-up to ...

This final season may be more of a cliffhanger than a conclusion. (A sequel is in the works.) The question it asks is: how ...